my-server
← Wiki

List of investigational hair loss drugs

This is a list of investigational hair loss drugs, or drugs that are currently under development for clinical use in the treatment of different forms of alopecia (hair loss), such as androgenetic alopecia (pattern hair loss) and alopecia areata (spot baldness), but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Route – Indication – Mechanism of Action [Reference]".

This list was last comprehensively updated in July 2025. It is likely to become outdated with time.

Under development

Preregistration

  • Coacillium (LH-8) – topical, other routes – alopecia areata, alopecia – various mechanisms of action
  • Gecaxitinib (gecacitinib, jaktinib) – oral – alopecia areata – ACVR1 protein inhibitor, Janus kinase 1 inhibitor, Janus kinase 2 inhibitor, Janus kinase 3 inhibitor, TYK2 kinase inhibitor
  • Ivarmacitinib (ARQ-252, ARQ-255, SHR-0302) – oral – alopecia areata – Janus kinase 1 inhibitor

Phase 3

  • AB-103 – topical – alopecia – minoxidil sulfotransferase stimulant (adjunct to minoxidil)
  • Clascoterone (Breezula, Winlevi; CB-03-01) – topical – alopecia – androgen receptor antagonist
  • Diphencyprone (diphenylcyclopropenone, samcyprone) – topical – alopecia areata – immunomodulator
  • Dutasteride (AD-208) – oral – alopecia – 5α-reductase inhibitor
  • Minoxidil oral extended-release (VDPHL01, VDPHL-01, VDPHL) – oral – alopecia, male pattern baldness – potassium channel opener (prodrug of minoxidil sulfate)
  • Minoxidil sublingual (SLM) – sublingual – alopecia – potassium channel opener (prodrug of minoxidil sulfate)
  • Pyrilutamide (EX-A5504, HY-145451, KX 826) – topical – alopecia – androgen receptor antagonist
  • Upadacitinib (Rinvoq; ABT-494) – oral – alopecia areata – Janus kinase 1 inhibitor

Phase 2/3

  • Dalosirvat (SM-04554) – topical – alopecia – Wnt signalling pathway stimulant

Phase 2

  • Abatacept (Orencia) – injection – alopecia areata – T cell activation inhibitor
  • Amlitelimab (KY-1005, SAR-445229) – subcutaneous injection – alopecia areata – OX40 ligand inhibitor
  • BAY-1158061 (HMI-115) – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody (prolactin receptor inhibitor)
  • Bempikibart (ADX-914, BMS-986265) – subcutaneous injection – alopecia areata – CRLF2 protein antagonist, interleukin 7 receptor α subunit inhibitor
  • Bimatoprost (Lumigan) – topical – alopecia – prostaglandin F receptor agonist (prostaglandin F<sub>2α</sub> analogue)
  • Botulinum toxin A (Xeomin; incobotulinum toxin A) – intradermal – alopecia – acetylcholine release inhibitor and neuromuscular blocking agent
  • CKD-498 – oral – alopecia – undefined mechanism of action
  • Daxdilimab (HZN-7734; MEDI-7734; VIB-7734) – oral – alopecia areata – anti-ILT7 human monoclonal antibody/dendritic cell inhibitor
  • Delgocitinib (Anzupgo, Corectim; JTE-052, LEO-124249, LP-0133) – unknown – alopecia areata – Janus kinase inhibitor
  • Deucravacitinib (Sotyktu; BMS-986165) – oral – alopecia areata – TYK2 kinase inhibitor
  • Finasteride/latanoprost/minoxidil (TH-07; Triple Hair) – topical – alopecia – combination drug/multiple mechanisms of action
  • FOL-005 (osteopontin-derived peptide) – intradermal – alopecia – undefined mechanism of action
  • GT-20029 (AR-PROTAC) – topical – alopecia – androgen receptor degradation enhancer
  • KL-130008 – oral – alopecia areata – Janus kinase inhibitor
  • Latanoprost (DLQ01; DLQ-01) – topical – androgenic alopecia – prostaglandin F receptor agonist (prostaglandin F<sub>2α</sub> analogue)
  • NXC-736 – oral – alopecia areata – sphingosine 1 phosphate receptor antagonist
  • PP405 (PP-405) – topical – alopecia – mitochondrial pyruvate carrier (MPC) inhibitor
  • Rezpegaldesleukin (Rezpeg; LY-3471851, NKTR-358) – unknown – alopecia areata – interleukin-2 conjugate/modulator
  • RK-023 (nobiprostolan) – topical – alopecia, hypotrichosis – undefined mechanism of action (prostaglandin F<sub>2α</sub> analogue)
  • Rosnilimab (ANB-030) – subcutaneous injection – alopecia areata – programmed cell death 1 receptor agonist
  • Ruxolitinib (Jakafi, Jakavi, Opzelura; INCB-018424) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor
  • SIS-302-AA – unspecified – alopecia areata – undefined mechanism of action
  • SYHX-1901 – oral – alopecia areata – Janus kinase inhibitor, Syk kinase inhibitor
  • TDM-105795 (CU-40101) – topical – alopecia – thyroid hormone receptor agonist

Phase 1/2

  • ABS-201 – subcutaneous injection – alopecia – prolactin receptor monoclonal antibody
  • Finasteride (IVL-3001, IVL-3002) – long-acting injection – alopecia – 5α-reductase inhibitor
  • Finasteride (DA-4001, DA-4001C) – topical – alopecia – 5α-reductase inhibitor
  • IMG-007 (HMPL-A28) – intravenous injection – alopecia areata – OX40 receptor antagonist

Phase 1

  • AH-001 – topical – alopecia – ubiquitin-protein ligase expression stimulant
  • AMP-303 – intradermal – alopecia – undefined mechanism of action (polysaccharide)
  • CKD-843 – oral, injection – alopecia – undefined mechanism of action
  • CKR-051 – transdermal – alopecia – CXXC5 protein inhibitor, Wnt signalling pathway stimulant
  • DR-01 – parenteral – alopecia areata – antibody-dependent cell cytotoxicity, T lymphocyte stimulant
  • ET-02 (RS-5441) – topical – alopecia, hair disorders – undefined mechanism of action (targets and restores hair follicle stem cells)
  • FOL-100 – topical – alopecia – undefined mechanism of action
  • OLX-72021 – intradermal injection – alopecia – RNA interference
  • QY-201 – oral – alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor
  • SCO-240 – oral – alopecia – somatostatin receptor 5 modulator
  • Squaric acid dibutyl ester (SQX-770) – topical – alopecia areata – immunomodulator
  • VDAA – topical – alopecia areata – undefined mechanism of action

Phase 0

  • Latanoprost/minoxidil (ANR-001.1) – topical – hypotrichosis – combination drug/multiple mechanisms of action

Preclinical

  • AC-203 – unspecified – alopecia areata – cell death modulator
  • ADA-308 – topical – alopecia – androgen receptor antagonist
  • BMD-1141 (BMD-1341) – subcutaneous injection – alopecia – parathyroid hormone receptor agonist
  • Crebankitug (ZB-168) – parenteral – alopecia areata – interleukin 7 receptor α subunit inhibitor, thymic stromal lymphopoietin inhibitor
  • CS-12192 – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor, TBK1 protein inhibitor
  • ES-135 – parenteral – alopecia – fibroblast growth factor replacement
  • FB-102 – unknown – alopecia areata – interleukin-2 receptor β subunit antagonist
  • HCW-9302 – injection – alopecia areata – interleukin 2 replacement
  • MAX-40070 (MAX-3) – topical – alopecia areata – Janus kinase inhibitor, TYK2 kinase inhibitor
  • MEI-004 – unknown – alopecia – undefined mechanism of action
  • Oxymetazoline (DA-020) – topical – alopecia – α<sub>1</sub>-adrenergic receptor agonist
  • Phenylephrine/synephrine/tyramine (DA-007) – topical – alopecia – combination of phenylephrine (α<sub>1</sub>-adrenergic receptor agonist), synephrine (α<sub>1</sub>-adrenergic receptor agonist), and tyramine (norepinephrine–dopamine releasing agent)
  • YR-001 – topical – alopecia – ion channel antagonist

Research

  • SP-16 (Serpin Peptide 16) – unspecified – alopecia areata – immunomodulator, LDL receptor agonist
  • TRN-007 – unspecified – hair disorders – RNA interference

Phase unknown

  • JV-HG1 – topical – hair disorders – undefined mechanism of action
  • OMA-102 – oral – alopecia – undefined mechanism of action

Not under development

Development suspended

  • EQ-101 (BNZ132) – intravenous – alopecia areata – interleukin 15 receptor antagonist, interleukin 2 receptor antagonist, interleukin 9 receptor antagonist
  • Research programme: SNA based alopecia therapeutics - Exicure/AbbVie – alopecia – gene expression modulators
  • XCUR-17 – topical – alopecia – RNA interference

No development reported

  • AB-101 (RJ-101) – topical – alopecia – undefined mechanism of action
  • BRM-421 (GPN-00136, PDSP) – topical – alopecia – cell proliferation stimulant
  • Dimethylcurcumin (ASC-J9, AJ-101) – topical – male pattern baldness – androgen receptor degradation enhancer
  • Lepzacitinib (ATI-1777) – topical – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor
  • PF-277343 – unspecified – alopecia – undefined mechanism of action
  • Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharm – unknown – alopecia areata – Janus kinase 3 inhibitors
  • Research programme: skin diseases therapeutics - Quark Pharmaceuticals (QP-AL1; QP-AL2) – unknown – alopecia (chemotherapy-induced) – RNA interference
  • Research programme: stem cell therapeutics - Histostem (Cirrhosis HMScs) – unknown – alopecia – cell replacement
  • Synephrine (AB-102) – topical – alopecia – α<sub>1</sub>-adrenergic receptor agonist
  • Valproic acid (VPA spray) – topical – male pattern baldness – glycogen synthase kinase 3β inhibitor, Wnt signalling pathway stimulant

Discontinued

  • AS-601811 – oral – male pattern baldness – 5α-reductase inhibitor
  • ATI-501 (A-201; ATI-50001) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor
  • Brepocitinib (PF-06700841) – oral – alopecia, alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor
  • Cioteronel (CPC-10997; Cyoctol, X-Andron) – topical – alopecia – androgen receptor antagonist
  • Denileukin diftitox (Lymphirtm, Ontak, Remitoro; LY-335348; DAB389 interleukin-2) – unknown – alopecia – protein synthesis inhibitor
  • Epristeride (Aipuliete; ONO-9302, SKF-105657) – oral – alopecia – 5α-reductase inhibitor
  • Etrasimod (Verespiti, Velspity; APD-334, PF-07915503) – oral – alopecia areata – sphingosine 1 phosphate receptor modulator
  • Farudodstat (ASLAN-003, LAS-186323) – oral – alopecia areata – dihydroorotate dehydrogenase inhibitor
  • HST-001 (HSC-660) – intradermal – alopecia – intercellular signalling peptide and protein replacement
  • Ifidancitinib (A-301, ATI-50002, ATI-502) – topical – alopecia, alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor
  • MK-434 (MK-0434) – oral – alopecia – 5α-reductase inhibitor
  • Naminidil (BMS-234303) – topical – alopecia – potassium channel opener
  • NEOSH–101 – topical – alopecia – undefined mechanism of action
  • P-1075 – unknown – alopecia – potassium channel opener
  • Piliel – topical – alopecia – undefined mechanism of action
  • Research programme: androgen receptor antagonists - Endoceutics (EM-4350, EM-6537) – unknown – male pattern baldness – androgen receptor antagonists
  • Research programme: oligonucleotide therapeutics for alopecia - OliPass – unknown – alopecia – androgen receptor antagonists
  • RU-58841 (PSK-3841, HMR-3841) – topical – alopecia – androgen receptor antagonist
  • Secukinumab (Cosentyx) – injection – alopecia areata – IL17A protein inhibitor
  • Setipiprant (ACT-129968, KYTH-105) – oral – alopecia – prostaglandin D<sub>2</sub> receptor antagonist
  • Timbetasin (thymosin β4) – unknown – alopecia – various mechanisms of action
  • Tralokinumab (Adbry, Adtralza; CAT-354, LP-0162) – subcutaneous injection – alopecia areata – interleukin-13 inhibitor
  • TU-2100 – topical – hair disorders – undefined mechanism of action

Clinically used drugs

Approved drugs

Potassium channel openers

  • Minoxidil (Rogaine) – topical – alopecia – potassium channel opener (prodrug of minoxidil sulfate)

5α-Reductase inhibitors

  • Finasteride (Propecia) – oral – alopecia – 5α-reductase inhibitor
  • Finasteride (Finjuve) – topical – alopecia – 5α-reductase inhibitor
  • Dutasteride (Avodart) – oral – alopecia – 5α-reductase inhibitor

Androgen receptor antagonists

  • Topilutamide (fluiridil; Eucapil) – topical – alopecia – androgen receptor antagonist

Immunomodulators

  • Baricitinib (Olumiant) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitors, TYK2 kinase inhibitor
  • Deuruxolitinib (Leqselvi) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 2 inhibitor
  • Ritlecitinib (Litfulo) – oral – alopecia areata – Emt protein-tyrosine kinase inhibitor, Janus kinase 3 inhibitor

Others

  • Alfatradiol (Avicis, Avixis, Ell-Cranell Alpha, Pantostin) – oral – alopecia – dual weak estrogen and 5α-reductase inhibitor
  • Minoxidil/finasteride (MorrF) – topical – alopecia – combination of minoxidil (potassium channel opener) and finasteride (5α-reductase inhibitor)
  • Nepidermin (Easyef; DWP-401) – topical – alopecia – recombinant human epidermal growth factor (rhEGF) or epidermal growth factor receptor (EGFR) agonist

Off-label drugs

See also

References

External links